Chemomab Therapeutics (NASDAQ:CMMB) Stock Price Up 0.5% – Still a Buy?

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) shares traded up 0.5% during mid-day trading on Wednesday . The stock traded as high as $2.19 and last traded at $2.08. 217,347 shares changed hands during mid-day trading, an increase of 108% from the average session volume of 104,315 shares. The stock had previously closed at $2.07.

Wall Street Analyst Weigh In

Separately, Oppenheimer reissued an “outperform” rating and set a $11.00 price objective (down previously from $13.00) on shares of Chemomab Therapeutics in a report on Friday, November 15th.

Chemomab Therapeutics Stock Performance

The firm’s 50-day moving average price is $1.93 and its 200 day moving average price is $1.66. The company has a market cap of $28.43 million, a price-to-earnings ratio of -1.98 and a beta of 0.66.

Hedge Funds Weigh In On Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. Sphera Funds Management LTD. bought a new position in shares of Chemomab Therapeutics Ltd. (NASDAQ:CMMB) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,214,575 shares of the company’s stock, valued at approximately $1,907,000. Sphera Funds Management LTD. owned approximately 8.46% of Chemomab Therapeutics at the end of the most recent quarter. 46.05% of the stock is owned by institutional investors and hedge funds.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).